What is the official website of Novartis US ?

The official website of Novartis US is https://www.novartis.us/.

What is Novartis US's cybersecurity risk score?

Novartis US has an AI-generated cybersecurity risk score of 776 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis US experienced?

According to Rankiteo, Novartis US currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis US been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis US has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis US have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis US is not certified under SOC 2 Type 1.

Does Novartis US have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis US does not hold a SOC 2 Type 2 certification.

Does Novartis US comply with GDPR ?

According to Rankiteo, Novartis US is not listed as GDPR compliant.

Does Novartis US have PCI DSS certification ?

According to Rankiteo, Novartis US does not currently maintain PCI DSS compliance.

Does Novartis US comply with HIPAA ?

According to Rankiteo, Novartis US is not compliant with HIPAA regulations.

Does Novartis US have ISO 27001 certification ?

According to Rankiteo,Novartis US is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis US operate in ?

Novartis US operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis US have ?

Novartis US employs approximately None employees people worldwide.

Does Novartis US own any subsidiaries ?

Novartis US presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis US have ?

Novartis US's official LinkedIn profile has approximately 201,696 followers.

What is the NAICS classification code for Novartis US ?

Novartis US is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis US have a Crunchbase profile ?

No, Novartis US does not have a profile on Crunchbase.

Does Novartis US have a LinkedIn profile ?

Yes, Novartis US maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-us.

How many cybersecurity incidents has Novartis US experienced ?

As of October 8, 2026, Rankiteo reports that Novartis US has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis US have ?

Novartis US has an estimated 5,774 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis US faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis US

Boost Score +25 with badge (5 left)

776

/1000

Fair

801

/1000

Good

Novartis US Vendor Cyber Rating & Cyber Score

novartis.us

Add Your Compliance Badge

We are an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. See our community guidelines: https://go.novartis.social/4bqbjuA

Novartis US

Novartis US CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis US

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis US Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis US

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis US in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis US in 2026.

Incident Types Novartis US vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis US in 2026.

Incident History - Novartis US (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis US Subsidiaries

Novartis US

Pharmaceutical Manufacturing

Website: https://www.novartis.us/

Company Size: 10,001+ employees

Novartis Gene TherapiesBiotechnology Research

NovartisPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Loading…

Novartis US Similar Companies

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Johnson & Johnson Innovative Medicine

jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Servier

servier.com

Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Loading…

NEWS

Novartis US CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 22, 2026 12:19 AM

Novartis Gets Win On Entresto Patent Tied To Earlier Ruling

A Delaware federal judge found Wednesday that MSN Pharmaceuticals Inc. infringed a patent covering Novartis Pharmaceuticals Corp.

Read Article

January 20, 2026 10:10 AM

Novartis expects to eliminate US tariff exposure by mid‑2026, CEO tells CNBC

Novartis CEO Vas Narasimhan told CNBC on Tuesday he expects the drugmaker's agreement with the U.S. government and its expanding...

Read Article

January 20, 2026 10:10 AM

Novartis’ U.S. deal could shield it from tariffs, CEO tells CNBC

Swiss pharmaceutical giant Novartis expects to "not really" be exposed to tariffs by the middle of the year, CEO Vas Narasimhan told CNBC at...

Read Article

January 20, 2026 10:00 AM

Novartis AG (NVS) Advances $23B U.S. Investment Plan With New RLT Logistics Hub

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Novartis AG is placed ninth on our list among the best cancer stocks.

Read Article

December 23, 2025 11:58 AM

Novartis, US Government Reach Agreement to Reduce Drug Prices

Revised Read about the agreement between Novartis and the US Government to reduce drug prices. A crucial step for medications like Entresto and Multiple...

Read Article

December 22, 2025 08:00 AM

Novartis, US government reach agreement to lower drug prices

Novartis has reached an agreement with the US government with the aim of reducing the price of innovative medicines and supporting continued...

Read Article

December 18, 2025 08:00 AM

Novartis, Roche back US efforts to lower drug costs amid talk of pricing deal

Swiss pharma giants Novartis and Roche on Thursday backed U.S. efforts to lower the cost of drugs and are working with the Trump...

Read Article

December 17, 2025 08:00 AM

Novartis, Roche near US drug price deal, Bloomberg News reports

The White House is set to announce drug pricing deals with pharmaceutical giants Novartis and Roche Holding as soon as Friday,...

Read Article

December 09, 2025 08:00 AM

Novartis AG (NVS) Announces US FDA Approval of Itvisma®

Novartis AG (NYSE:NVS) is one of the Most Undervalued Stocks to Buy Right Now. On November 24, the company announced that the US FDA...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-89322

SUMMARY

Vault and Vault Enterprise did not consistently evaluate ACL policies against the canonical form of resource and policy names. This may allow an authenticated user with delegated permissions to bypass an explicit deny restriction and access a protected resource or assign a denied policy, potentially leading to privilege escalation. This vulnerability (CVE-2026-89322) is fixed in Vault Community Edition 2.1.2, and Vault Enterprise 2.1.2, 1.21.12, 1.20.17, and 1.19.23.

Published

Date2026-10-07

Updated

Date2026-10-07

RISK INFORMATION (Score: 7.2)

cvss3

Base Score: 7.2

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.2

REFERENCES

https://discuss.hashicorp.com/t/hcsec-2026-43-vault-inconsistent-acl-policy-evaluation-may-allow-bypass-of-deny-restrictions/77815

CVE-2026-107314

SUMMARY

pgjdbc, the PostgreSQL JDBC Driver, versions 42.7.11 through 42.7.13 enforce no restriction when the requireAuth connection property excludes all six authentication methods the driver knows, for example requireAuth=!password,!md5,!gss,!sspi,!scram-sha-256,!none. The driver then accepts any method the server asks for, including cleartext password authentication. A value without a method in it, such as requireAuth=, (a single comma), is affected the same way. An attacker positioned between the application and its server can ask for cleartext password authentication and receive the database password. A positive list such as requireAuth=scram-sha-256, and a partial exclusion such as requireAuth=!password,!md5, are enforced correctly. The property has no default value, so a deployment that does not set it is not affected. 42.7.14 fixes the problem: such a connection is refused with SQLState 08004, and a value without a method in it is rejected as invalid.

Published

Date2026-10-07

Updated

Date2026-10-07

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.2

REFERENCES

https://github.com/pgjdbc/pgjdbc/security/advisories/GHSA-rhp9-mr79-r74h

CVE-2026-107285

SUMMARY

The AsyncHttpClient (AHC) library allows Java applications to easily execute HTTP requests and asynchronously process HTTP responses. Prior to 3.0.12 and 2.16.1, a proxied ws request is carried through CONNECT, but NettyRequestFactory.newNettyRequest and requestUri decide whether to attach proxy authentication and an absolute-form target only from whether the URI is secure. Because ws is not marked secure, the tunneled WebSocket upgrade sent to the origin includes the proxy's Proxy-Authorization value. Basic credentials are directly recoverable and Digest responses can be replayed or cracked offline. This issue is fixed in versions 3.0.12 and 2.16.1.

Published

Date2026-10-07

Updated

Date2026-10-07

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2026-107284

SUMMARY

The AsyncHttpClient (AHC) library allows Java applications to easily execute HTTP requests and asynchronously process HTTP responses. Prior to 3.0.12 and 2.16.1, WebSocketHandler.upgrade aborts a handshake whose Sec-WebSocket-Accept value is missing or invalid but continues into pipeline installation and onOpen delivery. Frames coalesced with the invalid 101 response can be decoded and delivered from a peer that did not prove the handshake, although the request future fails and the channel closes. This issue is fixed in versions 3.0.12 and 2.16.1.

Published

Date2026-10-07

Updated

Date2026-10-07

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:L/A:N

Impact Score

1.4

Exploitability

2.2

REFERENCES

CVE-2026-107283

SUMMARY

The AsyncHttpClient (AHC) library allows Java applications to easily execute HTTP requests and asynchronously process HTTP responses. Prior to 3.0.12 and 2.16.1, Realm.Builder generates the HTTP Digest client nonce with ThreadLocalRandom rather than a cryptographically secure random source. Digest relies on an unpredictable cnonce to resist chosen-plaintext and credential precomputation attacks, so an observer able to infer generator state can reduce the protection of the authentication exchange. This issue is fixed in versions 3.0.12 and 2.16.1.

Published

Date2026-10-07

Updated

Date2026-10-07

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

2.2

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Novartis US Vendor Cyber Rating & Cyber Score

Novartis US A.I CyberSecurity Scoring

Novartis US CyberSecurity News & History

Novartis US Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis US

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis US vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis US (X = Date, Y = Severity)

Novartis US Subsidiaries

Novartis US

Novartis US Similar Companies

Alkem Laboratories Ltd.

Lonza

Sandoz

Johnson & Johnson Innovative Medicine

Lupin

Bristol Myers Squibb

AbbVie

Servier

Astellas Pharma

Novartis US CyberSecurity News

Novartis Gets Win On Entresto Patent Tied To Earlier Ruling

Novartis expects to eliminate US tariff exposure by mid‑2026, CEO tells CNBC

Novartis’ U.S. deal could shield it from tariffs, CEO tells CNBC

Novartis AG (NVS) Advances $23B U.S. Investment Plan With New RLT Logistics Hub

Novartis, US Government Reach Agreement to Reduce Drug Prices

Novartis, US government reach agreement to lower drug prices

Novartis, Roche back US efforts to lower drug costs amid talk of pricing deal

Novartis, Roche near US drug price deal, Bloomberg News reports

Novartis AG (NVS) Announces US FDA Approval of Itvisma®

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Novartis US CyberSecurity News & History

Novartis US Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis US

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis US vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis US (X = Date, Y = Severity)

Novartis US Subsidiaries

Novartis US

Novartis US Similar Companies

Alkem Laboratories Ltd.

Lonza

Sandoz

Johnson & Johnson Innovative Medicine

Lupin

Bristol Myers Squibb

AbbVie

Servier

Astellas Pharma

Novartis US CyberSecurity News

Novartis Gets Win On Entresto Patent Tied To Earlier Ruling

Novartis expects to eliminate US tariff exposure by mid‑2026, CEO tells CNBC

Novartis’ U.S. deal could shield it from tariffs, CEO tells CNBC

Novartis AG (NVS) Advances $23B U.S. Investment Plan With New RLT Logistics Hub

Novartis, US Government Reach Agreement to Reduce Drug Prices

Novartis, US government reach agreement to lower drug prices

Novartis, Roche back US efforts to lower drug costs amid talk of pricing deal

Novartis, Roche near US drug price deal, Bloomberg News reports

Novartis AG (NVS) Announces US FDA Approval of Itvisma®

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo